Hamid Namini

2.0k total citations · 1 hit paper
21 papers, 1.2k citations indexed

About

Hamid Namini is a scholar working on Epidemiology, Oncology and Hepatology. According to data from OpenAlex, Hamid Namini has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 7 papers in Oncology and 7 papers in Hepatology. Recurrent topics in Hamid Namini's work include Hepatitis B Virus Studies (8 papers), Hepatitis C virus research (6 papers) and CAR-T cell therapy research (5 papers). Hamid Namini is often cited by papers focused on Hepatitis B Virus Studies (8 papers), Hepatitis C virus research (6 papers) and CAR-T cell therapy research (5 papers). Hamid Namini collaborates with scholars based in United States, Philippines and Singapore. Hamid Namini's co-authors include Dennis F. Bandyk, Michael S. Conte, Gregory L. Moneta, Alexander W. Clowes, Lynn Seely, Russell H. Samson, Michael Belkin, Scott A. Berceli, Allen D. Hamdan and Todd J. Lorenz and has published in prestigious journals such as The Lancet, Blood and Cancer Research.

In The Last Decade

Hamid Namini

20 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

2006 479 citations Michael S. Conte, Dennis F. Bandyk et al. Journal of Vascular Surgery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hamid Namini United States	11	502	455	351	315	154	21	1.2k
John Rose United Kingdom	15	394 0.8×	622 1.4×	449 1.3×	284 0.9×	119 0.8×	50	1.2k
Ki Tae Yoon South Korea	19	267 0.5×	767 1.7×	744 2.1×	148 0.5×	120 0.8×	77	1.2k
Ameet Dhar United Kingdom	14	487 1.0×	622 1.4×	390 1.1×	223 0.7×	99 0.6×	25	1.2k
Giuseppe Tarantino Italy	19	431 0.9×	480 1.1×	621 1.8×	159 0.5×	71 0.5×	73	1.1k
Shin Akagawa Japan	10	577 1.1×	223 0.5×	163 0.5×	407 1.3×	157 1.0×	28	1.1k
Carlos E. Marroquin United States	18	472 0.9×	360 0.8×	446 1.3×	208 0.7×	149 1.0×	41	1.1k
Kazuhide Shimamatsu Japan	14	258 0.5×	714 1.6×	693 2.0×	134 0.4×	78 0.5×	33	1.1k
Dennis Eurich Germany	17	461 0.9×	444 1.0×	633 1.8×	162 0.5×	62 0.4×	66	1.0k
Steffen Manekeller Germany	20	598 1.2×	324 0.7×	475 1.4×	183 0.6×	94 0.6×	81	1.1k
Louise Barbier France	24	870 1.7×	440 1.0×	490 1.4×	370 1.2×	79 0.5×	75	1.5k

Countries citing papers authored by Hamid Namini

Since Specialization

Citations

This map shows the geographic impact of Hamid Namini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hamid Namini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hamid Namini more than expected).

Fields of papers citing papers by Hamid Namini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hamid Namini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hamid Namini. The network helps show where Hamid Namini may publish in the future.

Co-authorship network of co-authors of Hamid Namini

This figure shows the co-authorship network connecting the top 25 collaborators of Hamid Namini. A scholar is included among the top collaborators of Hamid Namini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hamid Namini. Hamid Namini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dholaria, Bhagirathbhai, Mehmet H. Kocoglu, Leyla Shune, et al.. (2025). A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort (Arm C). Transplantation and Cellular Therapy. 31(2). S38–S38.

Dholaria, Bhagirathbhai, Leyla Shune, Katherine McArthur, et al.. (2024). Abstract CT071: Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy. Cancer Research. 84(7_Supplement). CT071–CT071. 4 indexed citations

Henry, Jason T., David Oh, Joaquina Baranda, et al.. (2022). 728 Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers. Regular and Young Investigator Award Abstracts. A761–A761. 12 indexed citations

Costello, Caitlin, Adam D. Cohen, Krina K. Patel, et al.. (2020). Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies. Blood. 136(Supplement 1). 29–30. 60 indexed citations

Hari, Parameswaran, Anastasios Raptis, James R. Berenson, et al.. (2019). Abstract CT107: Phase I/II safety and pharmacokinetics of BION-1301 targeting APRIL, a proliferation-inducing ligand, in adults with relapsed or refractory multiple myeloma. Cancer Research. 79(13_Supplement). CT107–CT107. 1 indexed citations

Mair, Eric A., et al.. (2019). OTO-201 for the Treatment of Acute Otitis Externa: Results from a Phase 3 Randomized Clinical Study. Annals of Otology Rhinology & Laryngology. 128(6). 524–533. 4 indexed citations

Tai, Yu‐Tzu, John Dulos, Lars Guelen, et al.. (2018). APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM. Blood. 132(Supplement 1). 3209–3209. 5 indexed citations

Heyward, William L., Matthew Davis, Keith S. Reisinger, et al.. (2013). Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine. 31(46). 5300–5305. 91 indexed citations

Janssen, Robert S., Roberto Mangoo‐Karim, Pablo E. Pérgola, et al.. (2013). Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine. 31(46). 5306–5313. 61 indexed citations

10.

Janssen, Robert S., Sean Bennett, Hamid Namini, William L. Heyward, & Jacob T. Martin. (2013). 1426 IMMUNOGENICITY AND SAFETY OF TWO DOSES OF INVESTIGATIONAL HEPLISAV™ COMPARED TO THREE DOSES OF LICENSED HEPATITIS B VACCINE (ENGERIX-B®) IN TWO PHASE 3 TRIALS. Journal of Hepatology. 58. S574–S574. 2 indexed citations

11.

Sablan, Benjamin, Dong Joon Kim, Nina G. Barzaga, et al.. (2012). Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine. 30(16). 2689–2696. 54 indexed citations

12.

Conte, Michael S., Dennis F. Bandyk, Alexander W. Clowes, et al.. (2006). Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. Journal of Vascular Surgery. 43(4). 742–751.e1. 479 indexed citations breakdown →

13.

Conte, Michael S., Dennis F. Bandyk, Alexander W. Clowes, et al.. (2005). Risk factors, medical therapies and perioperative events in limb salvage surgery: Observations from the PREVENT III multicenter trial. Journal of Vascular Surgery. 42(3). 456–464. 114 indexed citations

14.

Heathcote, E. Jenny, Lennox J. Jeffers, Robert Perrillo, et al.. (2002). Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection. Journal of Hepatology. 36. 110–111. 10 indexed citations

15.

Benhamou, Yves, Vincent Thibault, Vincent Cálvez, et al.. (2002). Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. Journal of Hepatology. 36. 138–138. 11 indexed citations

16.

Schiff, Eugene R., P. Neuhaus, Didier Samuel, et al.. (2002). Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients. Journal of Hepatology. 36. 32–32. 12 indexed citations

17.

Benhamou, Y., Vincent Thibault, Vincent Cálvez, et al.. (2001). Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. The Lancet. 358(9283). 718–723. 221 indexed citations

18.

Heathcote, E. Jenny, Quang Minh Thai, Manuel Tsiang, et al.. (2001). Dynamics analyses provide insight into the influence of precore mutations on the mechanisms of viral CL. Journal of Hepatology. 34. 167–168. 2 indexed citations

19.

Minor, James M. & Hamid Namini. (1996). Analysis of clinical data using neural nets. Journal of Biopharmaceutical Statistics. 6(1). 83–104. 11 indexed citations

20.

Minor, James M., Hamid Namini, & G. A. Watson. (1996). Generalized ridge analysis with application to population pharmacokinetics/dynamics. Journal of Biopharmaceutical Statistics. 6(1). 105–114. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact